|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/11/2011 10:58:52 AM
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free drug delivery systems, today reported financial results for the second quarter ended June 30, 2011. Bioject reported revenues of $2.4 million for the quarter ended June 30, 2011, compared to revenues of $1.2 million in the comparable 2010 period. Product sales were $2.2 million in the 2011 period compared to $1.0 million in the comparable 2010 period. License and technology fees were $209,000 for the quarter ended June 30, 2011, compared to $117,000 in the comparable 2010 period. The Company reported operating income of $276,000 in the second quarter of 2011 compared to an operating loss of $593,000 in the second quarter of 2010. Included in the current quarter operating income is $155,000 of non-cash charges comprised of non-cash compensation expense related to the fair value of stock-based awards and stock funding of $49,000, compared to $197,000 in the comparable year ago period, and depreciation and amortization of $106,000 in the current quarter, compared to $138,000 in the prior year-ago period. Net income allocable to common shareholders for the second quarter of 2011 was $248,000 compared to a net loss allocable to common shareholders of $580,000 in the comparable 2010 period. Cash at June 30, 2011 totaled $0.9 million.
|
|
|
|
|
|
|
|
|
|
|